{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:01:20Z","timestamp":1791482480025,"version":"4.3.4"},"reference-count":0,"publisher":"ScopeMed","issue":"3-4","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":410,"URL":"https:\/\/\/?sec=licenseinfo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Inform Med"],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:p>Background: Anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDARE) can occur after herpes simplex encephalitis (HSE) and Japanese encephalitis (JE). We describe the clinical features of children with anti-NMDARE after viral encephalitis. Objective; This study aims to describe the clinical characteristics, laboratory findings, and treatment outcomes of these patients. Methods: We describe the clinical characteristics of 14 children of anti-NMDARE following viral encephalitis treated at National Children\u2019s Hospital from January 2021 to December 2022. Patients with evidence of viral reactivation or other antibodies were excluded. Results: There are 12 children with anti-NMDARE after HSE and 2 children after JE. The median age was 2.1 years (range 0.6-12.9), with 8 male patients. All patients (100%) had fever and seizures, while 50% exhibited focal neurological signs. No patients experienced movement disorders, psychiatric symptoms, or sleep disturbances during the viral encephalitis phase. In contrast, the most common symptoms during the anti-NMDARE phase were as follows: movement disorders in 92.9% (13\/14), recurrent or prolonged fever in 71.4% (10\/14), sleep disturbances in 64.3% (9\/14), seizures in 50% (7\/14), and psychiatric symptoms in 50% (7\/14). The median cerebrospinal fluid (CSF) white blood cell count in the viral encephalitis and anti-NMDARE phases was 57 (4-410) and 13 (2-48), respectively. The mean CSF protein concentration was 0.43 \u00b1 0.16 g\/L and 0.85 \u00b1 0.63 g\/L, respectively. Brain MRI was performed in both encephalitis phases for 10\/14 patients, with 8\/10 showing no new lesions. Conclusion:  There were differences in clinical symptoms and CSF findings between the two phases of encephalitis; however, most patients did not develop new lesions on brain MRI.<\/jats:p>","DOI":"10.5455\/aim.2024.32.184-189","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T14:41:06Z","timestamp":1739544066000},"page":"184","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Features of Children With Anti-N-Methyl-D-Aspartate Receptor Encephalitis Following Viral Encephalitis"],"prefix":"10.5455","volume":"32","author":[{"given":"Vu","family":"Phuong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phung","family":"Thuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen","family":"Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3407","container-title":["Acta Informatica Medica"],"original-title":[],"link":[{"URL":"https:\/\/www.ejmanager.com\/mnstemps\/6\/6-1739431337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T17:48:18Z","timestamp":1791481698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejmanager.com\/mnstemps\/6\/6-1739431337.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":0,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5455\/aim.2024.32.184-189","relation":{},"ISSN":["0353-8109"],"issn-type":[{"value":"0353-8109","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}